CSME

(redirected from clinically significant macular edema)
AcronymDefinition
CSMECARICOM Single Market and Economy
CSMECaribbean Single Market and Economy
CSMECanadian Society for Mechanical Engineering
CSMEClub Sportif Multisections d'Epinay-sur-Seine (French sports club)
CSMECSIRO (Commonwealth Scientific and Industrial Research Organisation) Sustainable Materials Engineering
CSMEClinically Significant Macular Edema
CSMECertified Social Media Expert
CSMEClub Sportif Municipal d'Eaubonne (French: Eaubonne Municipal Sports Club; Eaubonne, France)
CSMECenter for Science and Mathematics Education (North Dakota State University)
CSMEConfédération Syndicale Mondiale des Enseignants (French: World Confederation of Teachers)
CSMEControl Site Multiplexer and Exchange
CSMECertified Subject Matter Educator
References in periodicals archive ?
Out 0f 360 eyes, 87 (24.17 %) eyes had clinically significant macular edema (CSME) on presentation (Table 4).
Micropulse laser thus may offer a new, less aggressive laser approach in the treatment of clinically significant macular edema.
Liu, "Quantitative assessment of retinal thickness in diabetic patients with and without clinically significant macular edema using optical coherence tomography," Acta Ophthalmologica Scandinavica, vol.
Controlled trials have shown that pan retinal photocoagulation (PDR) in proliferative diabetic retinopathy (PDR) and grid laser/focal photocoagulation in "Clinically significant macular edema" (CSME) are effective in reducing vision loss by 50% or more.5-7
Data from DCCT demonstrated that LDL-C and total-C/HDL-C were associated with increased risk for developing Clinically Significant Macular Edema (CSME).
Criteria for Diagnosis of Clinically Significant Macular Edema
Currently, there is no standard treatment approach for improving outcomes of cataract extraction in diabetic patients with different degrees of clinically significant macular edema. Previous papers proposed a combined approach with intravitreal injection of humanized anti-VEGF monoclonal antibodies (ranibizumab, bevacizumab) or triamcinolone acetonide and cataract surgery in patient with DME [6-12].
So far the treatment of choice in clinically significant macular edema is focal laser photocoagulation.
They found subjects in the highest quartile for LDL cholesterol had an adjusted 3.8-fold greater risk of developing clinically significant macular edema than those in the lowest quartile (Diabetes 2004;53:2,883-92).
Three years after randomization, patients who received focal photocoagulation to treat clinically significant macular edema (CSME) exhibited a 50% reduction in the risk of moderate visual loss, compared to controls (12-24%).
A study carried out at Al Ibrahim Eye Hospital (2011) showed that 39.8% of patients registered at retinal clinic were suffering from DR out of which 45% were having Clinically Significant Macular Edema (CSME).5
Full browser ?